Yusuke Maeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yusuke Maeda has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Shigeo Toda
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
8 shared publications - Adham Jurdi
Natera, Inc., Austin, TX, USA
7 shared publications - Akiko Chino
Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
7 shared publications - Antony Tin
Natera, Inc. 4 , San Carlos, California
7 shared publications - Eiji Shinozaki
Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
7 shared publications - Erik Spickard
Natera, Inc, Austin, USA
7 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0023
Ileocecal CD5-Positive Diffuse Large B-Cell Lymphoma Presenting with Acute Obstructive Symptoms: A Case Report
INTRODUCTION: Primary gastrointestinal lymphoma is a rare form of extranodal non-Hodgkin lymphoma, accounting for approximately 1%–4% of all gastrointestinal malignancies. Among primary gastrointestinal lymphomas, involvement of the small intestine accounts for approximately 20%–30% of cases. CD5-positive diffuse large B-cell lymphoma (DLBCL) is a rare variant, representing approximately 5%–10% of all DLBCL cases and is associated with advanced age, extranodal involvement, and poorer prognosis. We report a rare case of ileocecal CD5-positive DLBCL presenting with acute obstructive symptoms.CASE PRESENTATION: An 80-year-old man presented with abdominal pain and fever. Contrast-enhanced CT demonstrated circumferential wall thickening in the ileocecal region with enlarged regional lymph nodes, resulting in marked luminal narrowing and raising suspicion for locally advanced right-sided colon cancer presenting with acute obstructive symptoms. Emergency laparoscopic right hemicolectomy was performed. Intraoperatively, the tumor appeared hard and showed dense adhesion to the duodenum, with suspected duodenal involvement. The gross specimen revealed an 8 × 7 × 4-cm ulcerated mass arising from the terminal ileum. Histopathology confirmed CD5-positive DLBCL (non-germinal center B-cell type), and regional lymph nodes were histologically negative (0/11). The postoperative course was uneventful, and the patient was referred to the hematology department. PET-CT was initially recommended but deferred by the patient; later imaging suggested disseminated disease, and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy was initiated, although the long-term outcome could not be confirmed.CONCLUSIONS: Malignant lymphoma should be considered in the differential diagnosis of acute obstructive symptoms, even when imaging findings suggest carcinoma. Prompt surgical intervention can facilitate definitive diagnosis and timely referral for systemic therapy in selected cases.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0023
Open AccessIleocecal CD5-Positive Diffuse Large B-Cell Lymphoma Presenting with Acute Obstructive Symptoms: A Case Report
INTRODUCTION: Primary gastrointestinal lymphoma is a rare form of extranodal non-Hodgkin lymphoma, accounting for approximately 1%–4% of all gastrointestinal malignancies. Among primary gastrointestinal lymphomas, involvement of the small intestine accounts for approximately 20%–30% of cases. CD5-positive diffuse large B-cell lymphoma (DLBCL) is a rare variant, representing approximately 5%–10% of all DLBCL cases and is associated with advanced age, extranodal involvement, and poorer prognosis. We report a rare case of ileocecal CD5-positive DLBCL presenting with acute obstructive symptoms.CASE PRESENTATION: An 80-year-old man presented with abdominal pain and fever. Contrast-enhanced CT demonstrated circumferential wall thickening in the ileocecal region with enlarged regional lymph nodes, resulting in marked luminal narrowing and raising suspicion for locally advanced right-sided colon cancer presenting with acute obstructive symptoms. Emergency laparoscopic right hemicolectomy was performed. Intraoperatively, the tumor appeared hard and showed dense adhesion to the duodenum, with suspected duodenal involvement. The gross specimen revealed an 8 × 7 × 4-cm ulcerated mass arising from the terminal ileum. Histopathology confirmed CD5-positive DLBCL (non-germinal center B-cell type), and regional lymph nodes were histologically negative (0/11). The postoperative course was uneventful, and the patient was referred to the hematology department. PET-CT was initially recommended but deferred by the patient; later imaging suggested disseminated disease, and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy was initiated, although the long-term outcome could not be confirmed.CONCLUSIONS: Malignant lymphoma should be considered in the differential diagnosis of acute obstructive symptoms, even when imaging findings suggest carcinoma. Prompt surgical intervention can facilitate definitive diagnosis and timely referral for systemic therapy in selected cases.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Clinical characteristics of patients with local regrowth
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Clinical characteristics of patients with local regrowth
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Detailed patient characteristics and the clinical course of each patient.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Detailed patient characteristics and the clinical course of each patient.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Treatment and pathology outcomes in patients with non-complete response who underwent surgery
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Treatment and pathology outcomes in patients with non-complete response who underwent surgery
- 7 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5188-5197
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117
- 7 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (24) , 5188-5197
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117